| 000 | 01604 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516152300.0 | ||
| 264 | 0 | _c20130909 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(13)70247-X _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPinilla-Dominguez, Pilar | |
| 245 | 0 | 0 |
_aNICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cJul 2013 |
||
| 300 |
_a691-2 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xeconomics |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCarboplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aRichardson, Joanna | |
| 700 | 1 | _aRobertson, Janet | |
| 700 | 1 | _aAdam, Jane | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 14 _gno. 8 _gp. 691-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(13)70247-X _zAvailable from publisher's website |
| 999 |
_c22780050 _d22780050 |
||